Free Trial
NASDAQ:BCTX

Briacell Therap 10/28/2024 Earnings Report

Briacell Therap logo
$7.87 +0.15 (+1.94%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$7.68 -0.20 (-2.48%)
As of 09/5/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Briacell Therap EPS Results

Actual EPS
-$10.50
Consensus EPS
-$78.00
Beat/Miss
Beat by +$67.50
One Year Ago EPS
N/A

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Briacell Therap Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Briacell Therap's next earnings date is estimated for Monday, October 27, 2025, based on past reporting schedules.

Conference Call Resources

Briacell Therap Earnings Headlines

HC Wainwright Predicts Stronger Earnings for Briacell Therap
HC Wainwright Forecasts Briacell Therap Q1 Earnings
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View Briacell Therap Profile

More Earnings Resources from MarketBeat